Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Impinj Inc (PI) vs Twist Bioscience Corp (TWST) Price & Performance

Impinj IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Impinj Inc vs Twist Bioscience Corp — how do they compare? Impinj Inc trades at $189.56 (market cap $5.60B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Twist Bioscience Corp for 27 Days on average.

PITWST
Market Cap
$5.60B$10.08B
Volume
9,9294,229,037
Sector
TechnologyHealth
52-Week High
$241.91$205.00
52-Week Low
$91.34$25.45
Typical Hold Time
22 Days27 Days
Enterprise Value
$5.73B$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Impinj Inc

Impinj (PI) trades at $189.16, down 0.98% on the day, with strong analyst support (16 buy ratings, 0 sell) and a consensus price target of $178.83. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though profitability remains negative with a -7.26% net income margin. Recent news highlights include upcoming Q3 earnings and CFO stock sales.

While technical indicators and analyst sentiment are positive, fundamental challenges persist with negative ROE and high valuation multiples. The company's RAIN RFID technology presents growth opportunities in logistics, but investors should weigh execution risks against the bullish consensus.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.

While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PI
100% Buy0% Sell
Avg holding period · 22 Days
TWST
100% Buy0% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Impinj Inc

Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.

Read more on PI →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →